Bioceltix is a Wrocław-based and internationally oriented biotechnological company developing innovative, both stem cells and secretome based products, for companion animals. Our flagship technology for manufacturing biopharmaceuticals for veterinary use utilizes the therapeutic potential of allogeneic stem cells (one donor – many recipients). Owning a GMP production facility, we provide single technology for several species, diseases, and routes of administration. Our cutting-edge approach will allow the product to be batch-produced and ready for off-the-shelf sale. The veterinary medicines, based on the immunomodulatory mechanism of action of MSC, will be an alternative to the symptomatic pharmacotherapy focused mainly on alleviating pain and inflammation. Our goal is to create analgesic and anti-inflammatory biopharmaceuticals that will induce the natural mechanisms of regenerating tissues affected by the disease. In our pipeline we have products intended for the treatment of atopic dermatitis and osteoarthritis in dogs and of osteoarthritis in horses – all in the advanced development stage. The registration procedure for BCX-CM-J and BCX-EM in the European Medicines Agency has been launched. We are led by the motto: “More than animal. More than technology.”
我们正在追踪 Bioceltix 的市场扩张
Bioceltix 的国际扩张与竞争对手的对比情况
Bioceltix你条形图显示所对比公司之间的相对规模。
列5| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
 Bioceltix你 | 0 | 0 | — | 0 | 0 |
当前没有招聘
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
没有进行中的营销活动
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 Bioceltix 的业务、市场和增长信号的快速解答。
